The Journal of Nutrition has published results of a comparative clinical pharmacokinetic study reportedly demonstrating the bioavailability of curcuminoids is impacted significantly by the different delivery technologies used to formulate the turmeric ingredients.
The clinical study was randomised, cross-over, and involved 30 healthy adults, 24-hour kinetics, a consistent delivery format and clear statistical plan, along with an exhaustive quantification of curcuminoids metabolites. It compared five turmeric products consumed orally at their recommended daily dose for efficacy: standard turmeric extract, piperine-curcuminoid combination, phytosome formulation, liquid micellar preparation and natural patented dried colloidal suspension turmeric formulation, TurmiPure Gold.
The researchers found a low dose of TurmiPure Gold reportedly delivered significantly more curcuminoids in blood than a higher dose of any of the other four formulas tested. Across the study period, a 300 mg dose of TurmiPure Gold was shown to deliver as many curcuminoids to the blood as 1,920mg of standard turmeric extract or 2,260mg of a piperine-curcuminoid blend.
The study shed light on the proportion of free curcumin vs metabolites really absorbed, but also on dose impact on bioavailability, as well as calling into question the need for piperine to maximise absorption.
Pascale Fança-Berthon, Category Technical Leader, Health at Givaudan, said: “Publication of this paper in such a reputable journal underlines the quality of the science involved in this study. The results indicate that TurmiPure Gold is the most bioavailable low-dose turmeric extract available on the market.”
Part of Givaudan’s Health Essentials botanical ingredients, TurmiPure Gold has been subjected to best-in-class human clinical trials to confirm its safety. It is generally recognised as safe (GRAS) by an expert panel in the US, making it suitable for food & beverage applications.